A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

What this study is about

The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.

Who can join (things the study team will check)

✅ You may be able to join if…

• Participant has regular menstrual cycles ≥24 days and ≤34 days
• A minimum 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition
• A history of menstrual migraine attacks of at least 3 months
• Participant reported history of experiencing at least 1 migraine attack during the perimenstrual period in at least 2 out of 3 menstrual cycles immediately prior to screening.
• If the participant is receiving a permitted background continuous prophylactic migraine medication, the medication dose must be stable for at least 3 months prior to the Screening visit and, the dose is not expected to change during the course of the study

🚫 You may not be able to join if…

• Greater than 6 migraine days per month that are outside of the perimenstrual period in the 3 months prior to Screening
• A diagnosis of chronic migraine or a history of more than 14 headache days per month on average, in the 3 months prior to Screening
• History of retinal migraine, basilar migraine or hemiplegic migraine
• Current diagnosis of schizophrenia, bipolar, or borderline personality disorder
• Other pain syndromes (eg, fibromyalgia, complex regional pain syndrome), or significant neurological disorders (other than migraine), or other medical conditions (including endocrine and gynecological eg, severe dysmenorrhea

Where this trial is running

• Mayo Clinic Hospital, Phoenix, Arizona, United States
• Mayo Clinic Specialty Building, Phoenix, Arizona, United States
• Mayo Clinic Arizona, Scottsdale, Arizona, United States
• Hope Clinical Research, Inc., Canoga Park, California, United States
• Axiom Research, Colton, California, United States
• Diablo Clinical Research, Inc., Walnut Creek, California, United States
• VIN - Aventura, Aventura, Florida, United States
• Velocity Clinical Research, Hallandale Beach, Hallandale, Florida, United States
• Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
• Urban Family Practice Associates, Marietta, Georgia, United States
• Clinical Research Atlanta, Stockbridge, Georgia, United States
• St Luke's Clinic - Neurology, Meridian, Idaho, United States

+ 111 more sites.

Who to contact

Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06641466.